17. Subsequent Events

Generation Bio Acquisition

In February 2026, the Company acquired Generation Bio through a tender offer for $4.2913 in cash per Generation Bio ordinary share and one non-transferrable CVR per share.

Repare Acquisition and XenoTherapeutics Arranger Letter

On November 14, 2025, the Repare Acquisition Agreement was executed, pursuant to which the Company acted as structuring agent in connection with the acquisition of Repare’s issued and outstanding common shares by Xeno. Xeno agreed to pay the Company an arranger fee of $3.0 million following the closing of the Repare acquisition for the services rendered, which fee was received in January 2026. BVF, a related party of the Company (Note 14), owned approximately 24.0% of Repare before its acquisition by Xeno.

The Repare acquisition closed on January 28, 2026.

Transition of Chief Financial Officer and Termination of Cash-Out Agreement

In January 2026, the Company announced the resignation of its then Chief Financial Officer, Mr. Burns, and the appointment of Mr. Jeffrey Trigilio as its new Chief Financial Officer. In conjunction with this transition, the Cash-Out Agreement was terminated as of Mr. Burns’ separation date (see Note 12). Mr. Burns’ vested stock options remain outstanding in accordance with their original terms.

Seralutinib Clinical Trial Results

In February 2026, Gossamer Bio announced topline results from the Phase 3 PROSERA clinical trial evaluating seralutinib for the treatment of pulmonary arterial hypertension. The trial did not meet its prespecified primary endpoint. Gossamer Bio plans to engage with regulatory authorities to discuss potential next steps for the seralutinib program. The Company is evaluating the impact of this development on its seralutinib‑related assets.